Compositions and methods for the prevention and/or treatment of a viral infection, in particular of the Coronaviridae family.

Multi-epitope, pan-coronavirus recombinant vaccine compositions featuring a combination of highly conserved B cell epitopes, highly conserved CD4+ T cell epitopes, and highly conserved CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The present invention uses several immuno-informatics and sequence alignment approaches and multiple immunological assays in vitro using human blood and saliva samples from COVID patients and healthy patients to identify several human B cells, CD4+ and CD8+ T cell epitopes that are highly conserved and antigenic in vitro. The Invention also used an in vivo unique mouse model of ACE2/HLA-A0201/HLA-DR triple transgenic mouse model to test the immunogenicity and the protective efficacy against SARS-CoV-2 infection and COVID-Like symptoms, of the identified B and T cell epitopes and of the resulting multi-epitope-pan-Coronavirus vaccine candidates. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of Coronaviruses mutations.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

Disclosed herein are methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).

The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.

The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules comprising a heavy chain comprising an alpha-1 domain and an alpha-2 domain connected by a disulfide bridge, wherein said MHC class I molecules are free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.

Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.

Provided is a method and a device for screening an antigen epitope polypeptide. The screening method includes: predicting one or more antigen epitopes with all proteome sequences of a target coronavirus to obtain a predicted epitope region; screening a polypeptide with a differential response to a positive serum sample infected by the target coronavirus and a control serum sample with a polypeptide chip technology, and recording the polypeptide as a differential peptide fragment; comparing the differential peptide fragment with all proteome sequences of the target coronavirus to obtain a first conserved motif region; screening regions meeting epitope screening conditions from the predicted epitope region and the first conserved motif region to obtain the antigen epitope, wherein the epitope screening conditions comprise a non-phosphorylation region and/or an extracellular region of the target coronavirus.